Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, Harvard Medical School, Boston, MA, USA.
Mod Pathol. 2013 Feb;26(2):289-94. doi: 10.1038/modpathol.2012.153. Epub 2012 Sep 7.
Gastrointestinal stromal tumors (GISTs) are usually driven by mutations in KIT or PDGFRA, although 15% of GISTs in adults and >90% in children lack such mutations. The majority of gastric KIT/PDGFRA wild-type GISTs show distinctive morphological and clinical features and loss of expression of succinate dehydrogenase (SDH) B. Only a small subset of SDHB-deficient GISTs carries loss-of-function mutations in SDHB, SDHC, or SDHD. Because of the complexity of its locus (15 exons) and the presence of three pseudogenes, SDHA is rarely analyzed. Recently, mutations in SDHA were shown to lead to loss of expression of SDHA in a small group of paragangliomas. We sought to determine whether immunohistochemistry for SDHA could identify GISTs with SDHA mutations. Tumors (n=33) with pathological features of SDH-deficient GIST were analyzed for expression of SDHA and SDHB by immunohistochemistry, and SDHA exons were sequenced from tumors lacking SDHA expression. Exons harboring somatic mutations were examined in DNA from corresponding normal tissue. All 33 tumors showed loss of SDHB expression. A total of 9 out of 33 (27%) tumors also lacked expression of SDHA. SDHA-deficient GISTs affected five men and four women (median age 38 years). SDHA expression was intact in the 24 remaining tumors, including those with known SDHB (n=3) or SDHC (n=2) mutations. Nonsense (n=8) or missense (n=1) mutations in SDHA were identified in all SDHA-deficient tumors. Heterozygous mutations were also found in DNA from normal tissues from six patients with available material. Somatic loss of the second allele has been found in seven tumors, five by loss of heterozygosity, one by a 13-bp deletion, and one by a missense mutation. Loss of SDHA expression in GIST reliably predicts the presence of SDHA mutations, which represent a relatively common cause of SDH-deficient GIST in adults. Immunohistochemistry for SDHA can be used to select patients for SDHA-specific genetic testing.
胃肠道间质瘤(GIST)通常由 KIT 或 PDGFRA 突变驱动,尽管成人中 15%的 GIST 和儿童中 >90%的 GIST 缺乏此类突变。大多数胃 KIT/PDGFRA 野生型 GIST 具有独特的形态学和临床特征,并且琥珀酸脱氢酶(SDH)B 表达缺失。只有一小部分 SDHB 缺陷型 GIST 携带 SDHB、SDHC 或 SDHD 的功能丧失突变。由于其基因座(15 个外显子)的复杂性和三个假基因的存在,SDHA 很少被分析。最近,SDHA 突变导致一小部分副神经节瘤中 SDHA 表达缺失。我们试图确定 SDHA 免疫组化是否可以识别具有 SDHA 突变的 GIST。通过免疫组化分析具有 SDH 缺陷型 GIST 病理特征的肿瘤(n=33)中 SDHA 和 SDHB 的表达,并从缺乏 SDHA 表达的肿瘤中对 SDHA 外显子进行测序。在相应正常组织的 DNA 中检查含有体细胞突变的外显子。所有 33 个肿瘤均显示 SDHB 表达缺失。共有 9/33(27%)肿瘤也缺乏 SDHA 表达。SDHA 缺陷型 GIST 影响 5 名男性和 4 名女性(中位年龄 38 岁)。其余 24 个肿瘤 SDHA 表达完整,包括已知 SDHB(n=3)或 SDHC(n=2)突变的肿瘤。所有 SDHA 缺陷型肿瘤均发现 SDHA 无义(n=8)或错义(n=1)突变。在有可用材料的 6 名患者的正常组织 DNA 中也发现了杂合突变。在 7 个肿瘤中发现了第二个等位基因的体细胞丢失,其中 5 个通过杂合性丢失,1 个通过 13bp 缺失,1 个通过错义突变。GIST 中 SDHA 表达缺失可靠地预测 SDHA 突变的存在,这是成人 SDH 缺陷型 GIST 的一个相对常见原因。SDHA 免疫组化可用于选择患者进行 SDHA 特异性基因检测。